Cargando…

Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

Time to clinical response, a proxy for hospital “discharge readiness,” was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lodise, Thomas, Colman, Sam, Stein, Daniel S, Fitts, David, Goldberg, Lisa, Alexander, Elizabeth, Scoble, Patrick J, Schranz, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240345/ https://www.ncbi.nlm.nih.gov/pubmed/32462049 http://dx.doi.org/10.1093/ofid/ofaa145

Ejemplares similares

Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
por: Lodise, Thomas P, et al.
Publicado: (2020)

676. Health-Related Quality of Life (HRQoL) as Measured by the 12-Item Medical Outcomes Study Short-Form (SF-12) Among Adults With Community-Acquired Bacterial Pneumonia (CABP) Who Received Either Lefamulin (LEF) or Moxifloxacin (MOX) in Two Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trials (LEAP 1 and 2)
por: Lodise, Thomas, et al.
Publicado: (2019)

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Darpo, Borje, et al.
Publicado: (2019)

699. Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Lewis, James H, et al.
Publicado: (2019)

663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials
por: Shorr, Andrew F, et al.
Publicado: (2019)

2245. Oral 5-Day Lefamulin for Outpatient Management of Pneumonia Outcomes Research Team (PORT) Risk Class III/IV Community-Acquired Bacterial Pneumonia (CABP): Post Hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 Study
por: Schranz, Jennifer, et al.
Publicado: (2019)

717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Noninferiority Clinical Trials
por: Schranz, Jennifer, et al.
Publicado: (2019)

2233. Efficacy and Symptom Resolution by Visit in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Schranz, Jennifer, et al.
Publicado: (2019)

2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
por: File, Thomas, et al.
Publicado: (2018)

LB6. Oral Lefamulin Is Safe and Effective in the Treatment of Adults With Community-Acquired Bacterial Pneumonia (CABP): Results of Lefamulin Evaluation Against Pneumonia (LEAP 2) Study
por: Alexander, Elizabeth, et al.
Publicado: (2018)

The clinical efficacy of lefamulin in the treatment of elderly patients with community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

Clinical Utility of Lefamulin: If Not Now, When?
por: Mercuro, Nicholas J., et al.
Publicado: (2020)

Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin
por: Eraikhuemen, Nathaniel, et al.
Publicado: (2021)

Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial
por: Rhee, Chin Kook, et al.
Publicado: (2015)

Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities
por: File, Thomas M., et al.
Publicado: (2021)

Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin
por: Rodvold, Keith A
Publicado: (2019)

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
por: File, Thomas M, et al.
Publicado: (2019)

Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia
por: Adhikary, Shubham, et al.
Publicado: (2022)

Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
por: File, Thomas M, et al.
Publicado: (2020)

Health-Related Quality of Life as Measured by the 36-Item Short Form Survey Among Adults With Acute Bacterial Skin and Skin Structure Infections who Received Either Omadacycline or Linezolid in a Phase 3 Double-Blind, Double-Dummy Clinical Trial
por: Chitra, Surya, et al.
Publicado: (2021)

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

Comparison of Two pMDIs in Adult Asthmatics: A Randomized Double-Blind Double-Dummy Clinical Trial
por: Nam, Tae-Hyun, et al.
Publicado: (2022)

Lefamulin, a recently approved novel antibacterial agent to fight against community-acquired bacterial pneumonia
por: Choudhury, Shouvik, et al.
Publicado: (2021)

Clinical efficacy of Spasmofen(®) suppository in the emergency treatment of renal colic: a randomized, double-blind, double-dummy comparative trial
por: Yakoot, Mostafa, et al.
Publicado: (2014)

Oral Chinese herbal medicine for psoriasis vulgaris: protocol for a randomised, double-blind, double-dummy, multicentre clinical trial
por: Deng, Jingwen, et al.
Publicado: (2017)

Double-blind, randomized, double-dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain
por: Plapler, Pérola Grinberg, et al.
Publicado: (2016)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol
por: Kotsaki, Antigone, et al.
Publicado: (2022)

Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing
por: Wicha, Wolfgang W, et al.
Publicado: (2019)

Efficacy and tolerability of a fixed-dose moxifloxacin – dexamethasone formulation for topical prophylaxis in LASIK: a comparative, double-masked clinical trial
por: Campos, Mauro, et al.
Publicado: (2008)

A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients
por: Stricker, Kirstin, et al.
Publicado: (2008)

Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial
por: WANG, Zhiyang, et al.
Publicado: (2015)

Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses
por: Du, Xiwen, et al.
Publicado: (2021)

Tissue Distribution of [(14)C]-Lefamulin into the Urogenital Tract in Rats
por: Wicha, Wolfgang W., et al.
Publicado: (2022)

Effect of an Echinacea-Based Hot Drink Versus Oseltamivir in Influenza Treatment: A Randomized, Double-Blind, Double-Dummy, Multicenter, Noninferiority Clinical Trial
por: Rauš, Karel, et al.
Publicado: (2015)

Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial
por: Cao, Kegang, et al.
Publicado: (2016)

Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks
por: Chen, Xiao-Fan, et al.
Publicado: (2021)

Moxifloxacin Safety: An Analysis of 14 Years of Clinical Data
por: Tulkens, Paul M., et al.
Publicado: (2012)

Moxifloxacin: Clinically compatible contrast agent for multiphoton imaging
por: Wang, Taejun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_45tsujs0h3lkkblcg0dogtbn38